Adaptive Biotechnologies said on Monday it has signed two non-exclusive deals with Pfizer to support research in rheumatoid ...
Dec 15 () - Adaptive Biotechnologies said on Monday it has signed two non-exclusive deals with Pfizer to support ...
Privately owned, standalone infusion centers are providing an alternative to hospitals and doctors' offices for patients with ...
Kyverna has previously reported positive midstage data with miv-cel in generalised myasthenia gravis (gMG), another ...
Use of GLP-1 receptor agonists, which have shown to be effective in diabetes and obesity treatment, is expanding into other ...
From boosting the immune system to easing nausea — studies point to a long list of health benefits of the spice with the ...
Landmark results could pave the way for miv-cel to become the first FDA-approved CAR T-cell therapy for autoimmune disease; Company on track to submit BLA for stiff person syndrome in 1H 2026 Miv-cel ...
News archive including articles on Fund Managers, Fund Selection, Asset Allocation, Absolute Return, Offshore Investments, Tax Shelters, Insurance bonds. Baillie Gifford’s three stocks driving positiv ...
Under the TCR-antigen data licensing agreement, Adaptive will receive an upfront payment and additional future potential annual licensing fees under this non-exclusive, multi-year data access ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback